First Phase 1 Trial Participant Receives HTL0016878, Heptares’ Therapy for Cognitive Impairment in Alzheimer’s

First Phase 1 Trial Participant Receives HTL0016878, Heptares’ Therapy for Cognitive Impairment in Alzheimer’s
The first participant in a Phase 1 clinical trial of HTL0016878 as a treatment for cognitive impairment in Alzheimer’s disease is receiving the therapy, according to its developer, Heptares Therapeutics. Heptares, a subsidiary of Japan’s Sosei Group Corporation, and Ireland-based Allergan are partnering in the trial under a treatment development and commercialization agreement they announced in April 2016. HTL0016878 is

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Albus Manton says:

    14th International summit on Alzheimer disease, Dementia Care Research and Awareness scheduled on August 31–September 01 2018.

    To Bio News Services
    Greetings!!!

    I hereby take immense privilege Bio News Services to attend Alzheimer’s Summit 2018.

    Alzheimer’s Summit 2018 operating committee formally Bio News Services team to attend as Speakers/Delegates/Exhibitor at 14th International summit on Alzheimer disease, Dementia Care Research and Awareness scheduled on August 31–September 01 2018.

    For more information follow: https://alzheimers.global-summit.com/
    Alzheimer’s Summit 2018 Operating Committee requires the earliest acknowledgement to secure your slot in the agenda.

    Thank you for your time

    Best Regards,
    Albus Manton
    Program Coordinator
    Neurology and Neuroscience
    Alzheimer’s Summit 2018

Leave a Comment

Your email address will not be published. Required fields are marked *